the alcholics trial, page-11

Hi Bill


I completely agree with you about the share price. IMO it wont move until there is significant advancement on the revenue front. Whether thats the manufacturing license, Ropren pricing within Russia, initial Ropren orders, the licensing deal with Menarini, I don’t know which one it will be.

From my understanding the company has always stated that they will not release the specifics of the trial results via the ASX as this will detract from the journal articles when they are released. The company is of the opinion that if they announce all the technical information in ASX releases, then the journal editors will have no incentive to publish the articles. Now I appreciate that you are not suggesting they release all such technical information in ASX releases, and I suppose its up to Solagran to determine where the line is drawn.

Its been no secret that they have had the results for a while before releasing and that was due to securing the IP. As for why release the results today, that is the million dollar question. I think the reason for doing so will be uncovered in the fullness of time.. but there clearly IS a reason for announcing what they have today.

I would imagine that from the companys perspective, the first announcement regarding the patent applications as a result of this trial was informing the public about the nature of the results.
So yes they were never going to release the complete trial results via the ASX, and were (and are) always going to so in an appropriate journal. I have no problem with this.

I suppose it comes down to the fact that I am happy to believe what the company says with regard to its trial results, and await the opportunity to read in more detail in the appropriate journal.

As for your other nic’s… I suppose Bob Roberts would be one too :-)